Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve

NANot yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

August 1, 2027

Conditions
Diminished Ovarian Reserve (DOR)Primary Ovarian Insufficiency (Poi)Ovarian Failure, Premature
Interventions
DEVICE

Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection

Under general anesthesia, patients undergo lower abdominal liposuction (aspirate: 100-360 mL). ADRCs are immediately prepared bedside using the Celution® system (Cytori Therapeutics): Lipoaspirate is processed in a sterile container with automated separation, centrifugation, and resuspension (90-120 min). From the 5mL ADRCs suspension obtained, 0.5mL is reserved for QC (cell count/viability/surface markers); 4.5mL is injected bilaterally into ovarian stroma (2-2.5mL/ovary). Post-procedure, patients are monitored supine for 30 min for local/systemic reactions before discharge if stable.

Sponsors
All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

Cytori Therapeutics

INDUSTRY